Portal de Periódicos da CAPES

Schiff base formation by the lysyl and hydroxylysyl side chains of collagen

1968; Elsevier BV; Volume: 33; Issue: 5 Linguagem: Inglês

10.1016/0006-291x(68)90223-4

1090-2104

Roy C. Page, Earl P. Benditt, C Richard Kirkwood,

Diabetes, Cardiovascular Risks, and Lipoproteins

Glycated serum protein (GSP, measured as serum fructosamine concentration in μmol/L) is a product of glycation reaction between glucose and serum proteins in the blood circulation. GSP is used along with blood glucose, glycated hemoglobin (HbA1c), and glycated albumin as indicators of glycemic control for diabetic patients. However, a systematic comparison of the GSP levels in different types of human diseases has not been reported. In this study, 62,698 clinical lab test results of GSP levels in patients with 61 clinically defined diseases over the past 5 years in our hospital were retrieved and compared to that of 1861 clinical lab test results in healthy individuals. Based on the mean (SD), median, and p (− Log10 p) values, we found that patients with type 2 diabetes, hepatic encephalopathy, pancreatic cancer, healthy individuals > 65 years old, and cerebral arteriosclerosis had significantly (p < 0.05, − Log10 p > 1.30) increased whereas patients with 49/61 diseases including preeclampsia, nephrotic syndrome, sepsis, lupus erythematous, and leukemia had significantly decreased GSP levels compared to that of healthy controls. Among the 61 diseases, type 2 diabetes and leukemia had the highest − Log10 p values (> 274) and lupus erythematous, nephrotic syndrome, and gastric cancer had − Log10 p values > 140. Revealing the molecular mechanisms especially those underlying the decreased GSP levels in most of human diseases might make GSP levels serve more clinical purposes in future.